JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
About this episode
Host Jake New summarizes insights into the LEAP-010 study regarding treatment options for recurrent or metastatic head and neck cancer.
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT
More episodes of Journal of Clinical Oncology (JCO) Podcast
- Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
- Phase 2 Study of Multi-Cancer Detection from Breath Samples
- JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
- JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
- JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
- JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
Explore listener stats, chart rankings, contacts and more on the Journal of Clinical Oncology (JCO) Podcast podcast page.